CAMBRIDGE, Mass., March 28, 2024 /PRNewswire/ -- XtalPi Inc., a leading global technology company in integrating artificial intelligence (AI) and robotics to advance the discovery of groundbreaking medicine and innovative materials, announced today the launch of its proprietary comprehensive solid form discovery and selection platform, XtalGazer. This advanced platform aims to significantly improve the polymorph selection process for the pharmaceutical industry by integrating AI- and automation-powered experimental and computational approaches.
BEIJING and HONG KONG, March 28, 2024 /PRNewswire/ -- XtalPi, a leading global technology company in integrating artificial intelligence (AI) and robotics to advance the discovery of groundbreaking medicine and innovative materials, today announced it will present a poster showcasing the latest accomplishments of its AI-powered platform for designing cancer vaccines at the 2024 American Association for Cancer Research (AACR) Annual Meeting. The meeting will take place from 5th – 10th April 2024 in San Diego, California, and XtalPi's poster will be included in the online Proceedings of the AACR.
SHANGHAI and BOSTON, Sept. 5, 2023 /PRNewswire/ -- XtalPi, a global leader in AI-powered drug discovery, and Parthenon Therapeutics, a clinical-stage biotechnology company dedicated to reprogramming the tumor microenvironment, announced their collaboration today to discover novel therapeutic antibodies for the treatment of solid tumors.
XtalPi’s AI tech has helped its pharma partners pinpoint dozens of potential drug candidates—and Eli Lilly wants a piece of the AI drug discovery pie.
CAMBRIDGE, Mass., May 30, 2023 /PRNewswire/ -- Today, XtalPi Inc., a pioneering pharmaceutical technology company powered by artificial intelligence (AI) and automation, announced an AI drug discovery collaboration of up to $250 million in upfront and milestone payments with Eli Lilly and Company. The collaboration will leverage XtalPi's integrated AI capabilities and robotics platform to de novo design and deliver drug candidates for an undisclosed target.
Merck & XtalPi Collaboration Optimizes Drug Formulations with AI-Powered Techniques
Merck and XtalPi Inc., a pharmaceutical technology company powered by artificial intelligence (AI) and automation, jointly published a study that highlights the benefits of combining computational workflows with wet lab experiments to advance drug development.
SHENZHEN, China, Jan. 11, 2023 /PRNewswire/ -- XtalPi, Inc., a pioneering pharmaceutical technology company powered by artificial intelligence (AI) and automation, announced that Dr. Sarah Trice has joined the company as chief operating officer of U.S. operations. Dr. Trice will report directly to XtalPi CEO Dr. Jian Ma, leading the company's growth strategy and corporate operations in the U.S. and European markets.
XtalPi and EDDC collaborate in AI-empowered drug discovery program for Non-Small Cell Lung Cancer